Nursing Takes Time: Workload Associated With Administering Cancer Protocols

Johan de Raad, BSc, Kees van Gool, M.Ec, Marion Haas, PhD, Philip Haywood, M.Ec, Margaret Faedo, PhD, Gisselle Gallego, PhD, Sallie Pearson, PhD, and Robyn Ward, PhD

New medicines and therapeutic combinations are tested and marketed every year. Healthcare decision makers have to make explicit choices about adopting new treatments and deal with the resource consequences of their choices. The aim of this article is to examine the nursing workload of administering alternative chemotherapy protocols as a driver of costs. Data collection (focus groups with chemotherapy nurses and a survey of nurse unit managers) was conducted to ascertain the time required to undertake chemotherapy-related tasks and the sources of variability in six chemotherapy centers in New South Wales, Australia. Four task types (patient education, patient assessment, administration, and patient communication) were identified as being associated with administering chemotherapy. On average, patient education required 48 minutes during the first visit and 18.5 minutes thereafter, patient assessment took 20.3 minutes, administration averaged 23 minutes, and patient communication required 24.2 minutes. Each center treated an average of 14 patients per day. Each patient received 3.3 hours of staff time (1.7 hours of direct contact time and 1.6 hours of noncontact time). The result of this research will allow healthcare decision makers and evaluators to predict the amount of nursing time required to administer chemotherapy based on the characteristics of a wide range of chemotherapy protocols.

The field of oncology is a dynamic one. Many new medicines appear on the market every year, and new combination therapies are continually being tested and evaluated. At the same time, chemotherapy is expensive. A healthcare institution’s decision makers have to decide whether or not to adopt new treatments and, consequently, analyze and respond to the resource impact of those decisions.

The costs associated with chemotherapy can be grouped into three categories: the cost of the therapeutic agent, the cost of administration, and the cost associated with treating adverse events. Previous research has indicated that the cost of administering protocols may be an important driver of the overall chemotherapy costs (Danese et al., 2008; Hale, Cohen, Maughan, & Stephens, 2002; Hornberger, Reyes, Lubeck, & Valente, 2008).